CU2 Stock Chart & Stats
€2.32
€0.00(0.00%)
At close: 4:00 PM EDT
€2.32
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€1.01 - €2.96
Previous CloseN/A
Volume0.00
Average Volume (3M)177.00
Market Cap
€448.72M
Enterprise Value€606.88
Total Cash (Recent Filing)€56.26M
Total Debt (Recent Filing)€76.80M
Price to Earnings (P/E)―
Beta1.18
Next Earnings
Oct 29, 2026EPS Estimate
-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.03
Shares Outstanding201,524,900
10 Day Avg. Volume282
30 Day Avg. Volume177
Financial Highlights & Ratios
PEG Ratio0.99
Price to Book (P/B)6.11
Price to Sales (P/S)1.90
P/FCF Ratio46.07
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€3.87Price Target Upside66.73% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.04
Revenue Forecast (FY)€217.90M
Bulls Say, Bears Say
Bulls Say
Revenue Growth And GuidanceDouble-digit product growth and higher full-year guidance indicate expanding demand for Cerus’s blood-safety platform. Continued revenue gains can improve operating leverage, support investment in new indications, and strengthen customer and market adoption over the next several quarters.
Recurring Consumables ModelRevenue tied to recurring use of disposable processing sets creates repeat purchasing as blood centers and hospitals process patient components. This usage-based model can provide greater durability than one-time equipment sales and supports visibility as procedure volumes and adoption expand.
Improving Profitability TrajectorySustained positive adjusted EBITDA alongside a materially narrower net loss shows progress toward operating self-sufficiency. If revenue growth continues and cost discipline holds, improving profitability could enhance internal funding capacity and reduce dependence on external financing.
Bears Say
Continued GAAP LossesCerus has not yet converted its improving operating trajectory into consistent GAAP profitability. Ongoing net losses weaken retained capital and leave results more sensitive to execution, financing costs, and the timing of commercial or regulatory investments over the coming quarters.
Elevated LeverageDebt materially above equity makes the balance sheet less conservative and limits financial flexibility if operating performance weakens. Although refinancing reduced the term loan and may lower interest expense, leverage remains an important constraint on capital allocation and resilience.
Weak Cash ConversionRecent cash generation remains insufficiently consistent despite positive operating cash flow in 2024 and 2025. Slightly negative trailing free cash flow means Cerus may need to rely on working-capital management or borrowing to fund growth, limiting financial flexibility until conversion improves.
Cerus News
CU2 FAQ
What was Cerus Corp’s price range in the past 12 months?
Cerus Corp lowest stock price was €1.01 and its highest was €2.96 in the past 12 months.
What is Cerus Corp’s market cap?
Cerus Corp’s market cap is €448.72M.
When is Cerus Corp’s upcoming earnings report date?
Cerus Corp’s upcoming earnings report date is Oct 29, 2026 which is in 50 days.
How were Cerus Corp’s earnings last quarter?
Cerus Corp released its earnings results on Jul 30, 2026. The company reported -€0.009 earnings per share for the quarter, beating the consensus estimate of -€0.011 by €0.003.
Is Cerus Corp overvalued?
According to Wall Street analysts Cerus Corp’s price is currently Undervalued.
Does Cerus Corp pay dividends?
Cerus Corp does not currently pay dividends.
What is Cerus Corp’s EPS estimate?
Cerus Corp’s EPS estimate is -0.01.
How many shares outstanding does Cerus Corp have?
Cerus Corp has 201,524,900 shares outstanding.
What happened to Cerus Corp’s price movement after its last earnings report?
Cerus Corp reported an EPS of -€0.009 in its last earnings report, beating expectations of -€0.011. Following the earnings report the stock price went down -13.6%.
Which hedge fund is a major shareholder of Cerus Corp?
Currently, no hedge funds are holding shares in DE:CU2
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cerus Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€3.87 (66.73% Upside)
€3.87 (66.73% Upside)
Blogger Sentiment
Bullish
DE:CU2 Sentiment 100%
Sector Average 60%
Sector Average 60%
Insider Transactions
Sold Shares
Worth €45.9K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Positive
20 days / 200 days
Momentum
95.38%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-3.70%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Cerus Corp
Cerus Corporation operates as a biotechnology firm dedicated to advancing and marketing the INTERCEPT Blood System. This proprietary technology significantly enhances the safety of transfusable blood components by neutralizing biological threats, thereby reducing the risk of blood-borne pathogens. The company's product line includes INTERCEPT systems specifically engineered to deactivate pathogens in donated platelets and plasma. It also offers a dedicated INTERCEPT Blood System for the inactivation of harmful agents in red blood cell components. Furthermore, Cerus markets an INTERCEPT Blood System for Cryoprecipitation, which leverages its plasma technology to produce two key pathogen-reduced blood products: a cryoprecipitated fibrinogen complex for treating and controlling bleeding, particularly massive hemorrhages stemming from fibrinogen deficiency, and pathogen-reduced, cryoprecipitate-reduced plasma. Cerus distributes these platelet and plasma systems globally through a combination of its direct sales force and an extensive network of distributors, reaching markets in North America, Europe, the Commonwealth of Independent States, the Middle East, and Latin America. Established in 1991, Cerus Corporation maintains its corporate headquarters in Concord, California.
CU2 Company Deck
CU2 Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed predominantly positive momentum: double-digit product revenue growth, raised product and IFC guidance, consecutive quarters of positive adjusted EBITDA, meaningful debt refinancing benefits, regulatory progress (PMA submission and upcoming Phase 3 readout), and a clean quality audit. Counterbalancing items include a drop in gross margin (51.4% vs 55.2% prior year) driven by currency and inflationary pressures, reduced government contract revenue this quarter, modest operating cash use for inventory, and regulatory/penetration challenges in Asia-Pacific and for broader IFC adoption. On balance the positives (top-line growth, improving profitability measures, stronger balance sheet flexibility, and regulatory/clinical progress) outweigh the near-term headwinds.View all DE:CU2 earnings summariesCU2 Stock 12 Month Forecast
Average Price Target
€3.87
▲(66.73% Upside)
Technical Analysis
Tactile Systems Technology
―
Viemed Healthcare
―
Brainsway
―
Outset Medical
―
908 Devices
―